FY2026 Earnings Estimate for EYPT Issued By HC Wainwright

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) – Analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Eyepoint Pharmaceuticals in a report issued on Friday, November 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($3.64) per share for the year, down from their previous estimate of ($3.40). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.46) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q4 2026 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.43) EPS, Q4 2027 earnings at ($0.22) EPS and FY2027 earnings at ($1.56) EPS.

Several other analysts have also issued reports on the company. Cantor Fitzgerald lowered Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, August 17th. Royal Bank Of Canada decreased their price target on Eyepoint Pharmaceuticals to $1.00 and set a “sector perform” rating for the company in a research note on Tuesday, October 20th. Wall Street Zen upgraded Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. TD Cowen lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the stock from $20.00 to $4.00 in a research report on Wednesday, September 2nd. Finally, Chardan Capital lowered Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research report on Tuesday, August 18th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $21.85.

Read Our Latest Report on Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $0.30 on Tuesday. The business has a 50-day moving average of $2.24 and a 200-day moving average of $10.17. The stock has a market capitalization of $25.86 million, a price-to-earnings ratio of -0.08 and a beta of 1.84. Eyepoint Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.14). Eyepoint Pharmaceuticals had a negative return on equity of 146.17% and a negative net margin of 13,281.23%. The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.23 million.

Institutional Trading of Eyepoint Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its position in shares of Eyepoint Pharmaceuticals by 22.6% in the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock valued at $46,419,000 after acquiring an additional 663,439 shares during the period. Aberdeen Group plc increased its stake in shares of Eyepoint Pharmaceuticals by 52.0% during the 3rd quarter. Aberdeen Group plc now owns 3,053,945 shares of the company’s stock worth $9,986,000 after purchasing an additional 1,045,143 shares during the last quarter. Commodore Capital LP bought a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at about $36,414,000. Hsbc Holdings PLC bought a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at about $10,743,000. Finally, Stempoint Capital LP raised its holdings in shares of Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after purchasing an additional 456,915 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

(Get Free Report)

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.

Featured Articles

Earnings History and Estimates for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.